What should I do if I become drug-resistant after taking Enasidenib?

Enasidenib (Enasidenib) is a targeted drug used to treat patients with IDH2 gene mutations in acute myeloid leukemia (AML). Although it has achieved certain efficacy during treatment, some patients may develop drug resistance, which poses a challenge to subsequent treatment. When faced with ensidipine resistance, patients and doctors need to adopt effective response strategies.

First, for patients with ensidipine resistance, the mechanism of resistance needs to be carefully evaluated. Studies have shown that drug resistance may be related to the further development of IDH2 gene mutations in tumor cells, changes in metabolic pathways, or mutations in other related genes. Through genetic sequencing, it can be determined whether there are new mutations or other related genetic changes, thereby providing guidance for subsequent treatment.

After confirming the resistance mechanism, doctors may consider adjusting the treatment plan. Combination regimens, such as with other chemotherapy drugs or targeted therapies, may be chosen to increase efficacy. In addition, there are some emerging targeted therapies and immunotherapy, such as CAR-T cell therapy, which may provide new hope for drug-resistant patients. For individual patients, clinical trials are also an option worth considering, in which patients have the opportunity to receive the latest treatments and medications.

At the same time, doctors will also pay attention to the patient's overall health status and possible side effects after drug resistance. On this basis, an individualized treatment strategy is developed to ensure that patients receive the most suitable treatment option. It is also very important for patients to maintain a good lifestyle and enhance their own immunity. While receiving treatment, pay attention to a reasonable diet, ensure adequate rest, and enhance the body's resistance, which will help improve the treatment effect.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC6724422/